Babak Pazooki, MD
Endocrinology, Diabetes & Metabolism · Joliet, ILNPI 1396762316
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $526,612 of the $581,665 with a category attached, or 90.5%. 30 manufacturers reported payments, led by Lilly USA, LLC at 31.4% of the total. Among endocrinology, diabetes & metabolism clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 940 payments — averaging $618.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$183K
- Sanofi-aventis U.S. LLC$138K
- Novo Nordisk$118K
- AstraZeneca$64K
- Abbott$31K
- Merck$21K
- plus $28K from 24 others
What the payments were for
- Consulting fees$8,7382%
- Speaking & faculty fees$526,61291%
- Travel & lodging$28,3155%
- Food & beverage$17,6593%
- Education$3410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 261 | $182,918 |
| Sanofi-aventis U.S. LLC | 163 | $137,779 |
| Novo Nordisk | 197 | $117,981 |
| AstraZeneca | 99 | $63,918 |
| Abbott | 101 | $30,747 |
| Merck | 24 | $20,557 |
| Johnson & Johnson | 23 | $18,840 |
| Bayer | 12 | $5,086 |
| Madrigal Pharmaceuticals | 3 | $1,843 |
| Insulet Corporation | 5 | $237 |
| Amgen(2 entities) | 5 | $188 |
| Dexcom, Inc. | 9 | $174 |
| Corcept Therapeutics | 4 | $162 |
| BD | 2 | $155 |
| Shire North American Group Inc | 3 | $146 |
| Boehringer Ingelheim | 7 | $140 |
| Mannkind Corporation | 1 | $125 |
| Tolmar, Inc. | 1 | $108 |
| Amarin Pharma, Inc. | 1 | $107 |
| Chiesi USA, Inc. | 1 | $94 |
| Dynavax Technologies Corporation | 4 | $82 |
| AbbVie | 3 | $68 |
| Tandem Diabetes Care, Inc. | 4 | $53 |
| Radius Health, Inc. | 1 | $51 |
| Sequel Med Tech, LLC | 1 | $22 |
| BETA Bionics, Inc. | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$168,208
- SOLIQUA 100/33$69,002
- FARXIGA$62,056
- Ozempic$53,386
- RYBELSUS$47,065
- TZIELD$40,754
- TOUJEO$40,130
- STEGLATRO$19,945
- FREESTYLE LIBRE 3$19,890
- INVOKANA$18,435
- Tresiba$6,220
- FreeStyle Libre 2$5,063
- Kerendia$4,903
- FreeStyle Libre Pro$3,875
- REZDIFFRA$1,800
- FreeStyle Libre$375
- Wegovy$130
- AFREZZA$125
- Repatha$125
- NATPARA (PARATHYROID HORMONE)$122
How this compares
$581,665 in reported general payments places this provider in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 513 | $968,315 |
| FarxigaDapagliflozin Propanediol | 452 | $586,168 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 269 | $480,308 |
| MounjaroTirzepatide | 289 | $449,131 |
| JardianceEmpagliflozin | 233 | $335,565 |
| Tresiba Flextouch U-200Insulin Degludec | 122 | $212,669 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 250 | $181,868 |
| TrulicityDulaglutide | 88 | $151,347 |
| RybelsusSemaglutide | 80 | $149,412 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 60 | $99,157 |
| Humalog Kwikpen U-200Insulin Lispro | 36 | $91,186 |
| Tresiba Flextouch U-100Insulin Degludec | 103 | $83,521 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 48 | $73,577 |
| Humalog Kwikpen U-100Insulin Lispro | 175 | $63,971 |
| Novolog FlexpenInsulin Aspart | 168 | $63,116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $117,981 | $1,137,360637 claims |
| Lilly USA, LLCMounjaro, Trulicity | $182,918 | $600,478377 claims |
| AstraZenecaFarxiga | $63,918 | $586,168452 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $140 | $358,810264 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $137,779 | $108,67496 claims |
| MerckJanuvia, Janumet | $20,557 | $79,62857 claims |
| BayerKerendia | $5,086 | $44,81225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Joliet
- Wassim El HarakeJoliet$17K
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Ammar BayrakdarEvergreen Park$517K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
- Liana BillingsSkokie$295K
- Daniel SoArlington Heights$283K
- Silvana PannainChicago$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.